Publications
Elevated levels of circulating betahydroxybutyrate in pituitary tumor patients may differentiate prolactinomas from other immunohistochemical subtypes
Ijare, OB, Holan, C, Hebert, J, Sharpe, MA, Baskin, DS & Pichumani, K 2020, Scientific reports, vol. 10, no. 1, 1334. https://doi.org/10.1038/s41598-020-58244-8
A ”clickable” probe for active MGMT in glioblastoma demonstrates two discrete populations of MGMT
Raghavan, S, Baskin, DS & Sharpe, MA 2020, Cancers, vol. 12, no. 2, 453. https://doi.org/10.3390/cancers12020453
Proton magnetic resonance spectroscopy characterization of Rathke’s cleft cysts (RCCs): Relevance to the differential diagnosis of pituitary adenomas and RCCs
Ijare, OB, Sharpe, MA, Baskin, DS & Pichumani, K 2020, Cancers, vol. 12, no. 2, 360. https://doi.org/10.3390/cancers12020360
Metabolic fate of glucose in atypical meningioma studied by 13C NMR isotopomer analysis
Pichumani, K, Ijare, OB & Baskin, DS 2019, . in Metabolic fate of glucose in atypical meningioma studied by 13C NMR isotopomer. Proc. Intl. Soc. Mag. Reson. Med. 27 (2019) 2507 edn, vol. 27, Internatioal Society for magnetic resonance in medicine, pp. 2507.
Ex Vivo 1 H NMR study of pituitary adenomas to differentiate various immunohistochemical subtypes
Ijare, OB, Baskin, DS & Pichumani, K 2019, Scientific Reports, vol. 9, no. 1, 3007. https://doi.org/10.1038/s41598-019-38542-6
Fibrinogen chains intrinsic to the brain
Golanov, EV, Sharpe, MA, Regnier-Golanov, AS, Del Zoppo, GJ, Baskin, DS & Britz, GW 2019, Frontiers in Neuroscience, vol. 13, no. MAY, 541. https://doi.org/10.3389/fnins.2019.00541
Creutzfeldt astrocytes may be seen in IDH-wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins
Ballester, LY, Boghani, Z, Baskin, DS, Britz, GW, Olsen, R, Fuller, GN, Powell, SZ & Cykowski, MD 2018, Brain Pathology, vol. 28, no. 6, pp. 1012-1019. https://doi.org/10.1111/bpa.12604
Metabolism of fructose in B-cells: A 13C NMR spectroscopy based stable isotope tracer study
Ijare, OB, Baskin, DS, Sharpe, MA & Pichumani, K 2018, Analytical Biochemistry, vol. 552, pp. 110-117. https://doi.org/10.1016/j.ab.2018.04.003
Correction: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma [J Transl Med., 16, (2018) (142)] DOI: 10.1186/s12967-018-1507-6
Liau, LM, Ashkan, K, Tran, DD, Campian, JL, Trusheim, JE, Cobbs, CS, Heth, JA, Salacz, M, Taylor, S, DAndre, SD, Iwamoto, FM, Dropcho, EJ, Moshel, YA, Walter, KA, Pillainayagam, CP, Aiken, R, Chaudhary, R, Goldlust, SA, Bota, DA, Duic, P, Grewal, J, Elinzano, H, Toms, SA, Lillehei, KO, Mikkelsen, T, Walbert, T, Abram, SR, Brenner, AJ, Brem, S, Ewend, MG, Khagi, S, Portnow, J, Kim, LJ, Loudon, WG, Thompson, RC, Avigan, DE, Fink, KL, Geoffroy, FJ, Lindhorst, S, Lutzky, J, Sloan, AE, Schackert, G, Krex, D, Meisel, HJ, Wu, J, Davis, RP, Duma, C, Etame, AB, Mathieu, D, Kesari, S, Piccioni, D, Westphal, M, Baskin, DS, New, PZ, Lacroix, M, May, SA, Pluard, TJ, Tse, V, Green, RM, Villano, JL, Pearlman, M, Petrecca, K, Schulder, M, Taylor, LP, Maida, AE, Prins, RM, Cloughesy, TF, Mulholland, P & Bosch, ML 2018, Journal of Translational Medicine, vol. 16, no. 1, 179. https://doi.org/10.1186/s12967-018-1552-1
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Liau, LM, Ashkan, K, Tran, DD, Campian, JL, Trusheim, JE, Cobbs, CS, Heth, JA, Salacz, M, Taylor, S, DAndre, SD, Iwamoto, FM, Dropcho, EJ, Moshel, YA, Walter, KA, Pillainayagam, CP, Aiken, R, Chaudhary, R, Goldlust, SA, Bota, DA, Duic, P, Grewal, J, Elinzano, H, Toms, SA, Lillehei, KO, Mikkelsen, T, Walpert, T, Abram, SR, Brenner, AJ, Brem, S, Ewend, MG, Khagi, S, Portnow, J, Kim, LJ, Loudon, WG, Thompson, RC, Avigan, DE, Fink, KL, Geoffroy, FJ, Lindhorst, S, Lutzky, J, Sloan, AE, Schackert, G, Krex, D, Meisel, HJ, Wu, J, Davis, RP, Duma, C, Etame, AB, Mathieu, D, Kesari, S, Piccioni, D, Westphal, M, Baskin, DS, New, PZ, Lacroix, M, May, SA, Pluard, TJ, Tse, V, Green, RM, Villano, JL, Pearlman, M, Petrecca, K, Schulder, M, Taylor, LP, Maida, AE, Prins, RM, Cloughesy, TF, Mulholland, P & Bosch, ML 2018, Journal of Translational Medicine, vol. 16, no. 1, 142. https://doi.org/10.1186/s12967-018-1507-6
PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma
Sharpe, MA, Raghavan, S & Baskin, DS 2018, Oncotarget, vol. 9, no. 35, pp. 23923-23943. https://doi.org/10.18632/oncotarget.25246
Measurement of 13C turnover into glutamate and glutamine pools in brain tumor patients
Pichumani, K, Mashimo, T, Vemireddy, V, Ijare, OB, Mickey, BE, Malloy, CR, Marin-Valencia, I, Baskin, DS, Bachoo, RM & Maher, EA 2017, FEBS Letters, vol. 591, no. 21, pp. 3548-3554. https://doi.org/10.1002/1873-3468.12867
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
ACT IV trial investigators & ACT IV trial investigators 2017, The Lancet Oncology, vol. 18, no. 10, pp. 1373-1385. https://doi.org/10.1016/S1470-2045(17)30517-X
Combined Hybrid Microscopic and Endoscopic Transsphenoidal Surgery: Anatomy, Instrumentation, and Technique
Baskin, DS & Scranton, RA 2017, . in ER Laws, AA Cohen-Gadol, TH Schwartz & JP Sheehan (eds), Transsphenoidal Surgery: Complication Avoidance and Management Techniques. Springer International Publishing, pp. 167-190. https://doi.org/10.1007/978-3-319-56691-7_11
Transfer of Dyes and Drugs into Cells Using EGFR-Targeted Nanosyringes
Nilewski, LG, Singh, M, Baskin, DS, Tour, JM & Sharpe, MA 2017, ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.7b00138
Superior Petrosal Vein Sacrifice During Microvascular Decompression: Perioperative Complication Rates and Comparison with Venous Preservation
Liebelt, BD, Barber, SM, Desai, VR, Harper, R, Zhang, YJ, Parrish, RG, Baskin, DS, Trask, T & Britz, GW 2017, World Neurosurgery, vol. 104, pp. 788-794. https://doi.org/10.1016/j.wneu.2017.05.098
HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial
Ahmed, N, Brawley, V, Hegde, M, Bielamowicz, K, Kalra, M, Landi, D, Robertson, C, Gray, TL, Diouf, O, Wakefield, A, Ghazi, A, Gerken, C, Yi, Z, Ashoori, A, Wu, MF, Liu, H, Rooney, C, Dotti, G, Gee, A, Su, J, Kew, Y, Baskin, DS, Zhang, YJ, New, P, Grilley, B, Stojakovic, M, Hicks, J, Powell, SZ-E, Brenner, M, Heslop, H, Grossman, RG, Wels, WS & Gottschalk, S 2017, JAMA Oncology, vol. 3, no. 8, pp. 1094-1101. https://doi.org/10.1001/jamaoncol.2017.0184
Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature
AbdelBaki, MS, Waguespack, SG, Salceda, V, Jones, J, Stapleton, SL, Baskin, DS & Okcu, MF 2017, Journal of Neuro-Oncology, pp. 1-3. https://doi.org/10.1007/s11060-017-2554-1
Metabolic sculpting of the mitochondria, cell signaling and the cancer phenotype
Sharpe, MA, Ismail, N & Baskin, DS 2017, Translational Cancer Research, vol. 6, pp. S182-S188. https://doi.org/10.21037/tcr.2017.01.33
Fractionated Stereotactic Radiotherapy for Pituitary Adenomas: Single-Center Experience in 75 Consecutive Patients
Barber, SM, Teh, BS & Baskin, DS 2016, Neurosurgery, vol. 79, no. 3, pp. 406-17. https://doi.org/10.1227/NEU.0000000000001155
